ReGEN Biomedical focusses on growing large amounts of robust and reproducible small pieces of tissue (micro tissues) for toxicity- & pharma-screening. Functional micro-tissues present the next step in mimicking patient organs and represent the future of personalized medicine. We are building expertise on how to assemble the micro-tissues into functional pieces of human organs, so-called macro-tissues. The micro tissues also serve as building blocks for RM-therapies and will be assembled into functional macro tissues. It is the aim to fully automate all production platforms and equip these with advanced appropriate offline and inline quality control systems. The platform technology also enables this initiative to realize sales and licensing for specific drug screening opportunities and ex vivo disease models. The large-scale production is one of the foundations of the development of a new (manufacturing) industry around affordable Regenerative Medicine solutions.
| Website | https://www.regenbiomedical.com/ |
| Employees | 18 (13 on RocketReach) |
| Founded | 2021 |
| Industry | Biotechnology Research |
| Keywords | Tissue Engineering, Toxicity Testing, Drug Discovery, In Vitro Models, Organ-On-A-Chip, Bioprinting, Regenerative Medicine, Pharmaceutical Research, Biotechnology, Preclinical Testing, Cell Culture, In Vitro Toxicology, Drug Development, Biomedical Research, Pharmaceutical Development |
| Competitors | Medline Industries, LP, Zimmer Biomet, Integra LifeSciences, Organogenesis, Acelity, Kerecis, MediWound Ltd., Tissue Regenix Group, WoundMatrix, Systagenix Wound Management (Germany) GmbH pharmazeutische Produkte chemische Produkte +29 more (view full list) |
Looking for a particular ReGEN Biomedical employee's phone or email?
Marleen van Nuenen is the CEO of ReGEN Biomedical.
13 people are employed at ReGEN Biomedical.